Literature DB >> 20373259

Chemical modification of siRNA.

Elena L Chernolovskaya1, Marina A Zenkova.   

Abstract

siRNAs are widely used for the control of gene expression in molecular biology and experimental pharmacology. siRNA molecules are the most efficient and specific inhibitors of gene expression to have been discovered, acting at nanomolar and subnanomolar concentrations. Challenges associated with nuclease stability, selecting effective sequences, reducing off-target effects and achieving efficient delivery to target cells and tissues have significantly limited the biomedical applications of siRNA. However, chemical modification is a powerful tool for improving the properties of siRNA. This review examines recent data regarding chemical modifications used to develop potent effectors of gene silencing. The correlation between thermal stability and potency, and between nuclease resistance and duration of the silencing effect, are discussed with relation to chemically modified siRNAs.

Mesh:

Substances:

Year:  2010        PMID: 20373259

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN: 1464-8431


  19 in total

Review 1.  Designing highly active siRNAs for therapeutic applications.

Authors:  S Patrick Walton; Ming Wu; Joseph A Gredell; Christina Chan
Journal:  FEBS J       Date:  2010-12       Impact factor: 5.542

2.  Sensor and sensitivity: a screen for elite shRNAs.

Authors:  Daniela Castanotto
Journal:  Mol Ther       Date:  2011-05       Impact factor: 11.454

3.  MicroRNAs as Therapeutic Targets in Lung Disease: Prospects and Challenges.

Authors:  Tadashi Sato; Hario Baskoro; Stephen I Rennard; Kuniaki Seyama; Kazuhisa Takahashi
Journal:  Chronic Obstr Pulm Dis       Date:  2015-12-14

Review 4.  RNAi-based therapeutic strategies for metabolic disease.

Authors:  Michael P Czech; Myriam Aouadi; Gregory J Tesz
Journal:  Nat Rev Endocrinol       Date:  2011-04-19       Impact factor: 43.330

5.  Cellular activity of siRNA oligonucleotides containing synthetic isomorphic nucleoside surrogates.

Authors:  Dongwon Shin; Peter Lönn; Steven F Dowdy; Yitzhak Tor
Journal:  Chem Commun (Camb)       Date:  2015-01-31       Impact factor: 6.222

6.  Membrane anchored immunostimulatory oligonucleotides for in vivo cell modification and localized immunotherapy.

Authors:  Haipeng Liu; Brandon Kwong; Darrell J Irvine
Journal:  Angew Chem Int Ed Engl       Date:  2011-06-17       Impact factor: 15.336

7.  Chemical synthesis of site-specifically 2'-azido-modified RNA and potential applications for bioconjugation and RNA interference.

Authors:  Michaela Aigner; Markus Hartl; Katja Fauster; Jessica Steger; Klaus Bister; Ronald Micura
Journal:  Chembiochem       Date:  2011-01-03       Impact factor: 3.164

8.  Small interfering RNA targeted to IGF-IR delays tumor growth and induces proinflammatory cytokines in a mouse breast cancer model.

Authors:  Tiphanie Durfort; Mercedes Tkach; Mariya I Meschaninova; Martín A Rivas; Patricia V Elizalde; Alya G Venyaminova; Roxana Schillaci; Jean-Christophe François
Journal:  PLoS One       Date:  2012-01-03       Impact factor: 3.240

9.  Efficacy of a novel class of RNA interference therapeutic agents.

Authors:  Tomohiro Hamasaki; Hiroshi Suzuki; Hisao Shirohzu; Takahiro Matsumoto; Corina N D'Alessandro-Gabazza; Paloma Gil-Bernabe; Daniel Boveda-Ruiz; Masahiro Naito; Tetsu Kobayashi; Masaaki Toda; Takayuki Mizutani; Osamu Taguchi; John Morser; Yutaka Eguchi; Masahiko Kuroda; Takahiro Ochiya; Hirotake Hayashi; Esteban C Gabazza; Tadaaki Ohgi
Journal:  PLoS One       Date:  2012-08-15       Impact factor: 3.240

10.  Development of a 2',4'-BNA/LNA-based siRNA for Dyslipidemia and Assessment of the Effects of Its Chemical Modifications In Vivo.

Authors:  Shunsuke Wada; Satoshi Obika; Masa-Aki Shibata; Tsuyoshi Yamamoto; Moeka Nakatani; Tetsuji Yamaoka; Hidetaka Torigoe; Mariko Harada-Shiba
Journal:  Mol Ther Nucleic Acids       Date:  2012-09-18       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.